What Is Melanotan II? Benefits, Research & Safety
A synthetic analogue of alpha-melanocyte stimulating hormone researched for tanning effects and sexual function enhancement.
UK summary: Not a licensed UK medicine. Treated by the MHRA as a prescription-only medicine on the basis of its pharmacological effects. UK sale for human use is unlawful; the MHRA has actively warned the public against using it.
Quick Facts
Overview
Melanotan II — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Treated by the MHRA as a prescription-only medicine on the basis of its pharmacological effects. UK sale for human use is unlawful; the MHRA has actively warned the public against using it.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for any indication. Classified as a prescription-only medicine (POM) due to pharmacological activity. MHRA has issued warnings against use.
- EU: Not approved for any indication. Regulatory warnings issued in multiple member states.
- Notes: Melanotan II is not approved anywhere in the world for any indication. It is banned by WADA in sport. Regulatory agencies including MHRA, FDA, EMA, and TGA have issued explicit warnings about its use. Products sold are unregulated and may contain contaminants.
05Approved medical uses
- None for cosmetic tanning. Afamelanotide (Scenesse) is a separately-licensed product for the rare condition erythropoietic protoporphyria (EPP) via specialist NHS centres — not the consumer melanotan market.
06Unapproved / promotional claims
- Safe alternative to sunbeds
- Natural tan with no skin-cancer risk
- Bronze with no other effects
07Common internet claims
- Use the nasal spray for safer dosing
- Pair with sunbed sessions for ‘rapid bronze’
- Pharma-grade vials are safe at any dose
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Safe sunless tanning” | E | No | High | Documented adverse effects include nausea, blood-pressure changes, and effects on moles. No UK regulator has assessed it as safe for cosmetic tanning. |
| “Prevents skin cancer by replacing UV exposure” | E | No | High | There is no evidence Melanotan II reduces skin-cancer risk in humans, and effects on existing moles are a concern. |
| “Improves libido and erectile function” | C | Limited | High | Some preclinical and limited human signals exist; the derivative PT-141 (bremelanotide) is the licensed melanocortin product for sexual dysfunction in some jurisdictions, not Melanotan II. |
| “Sold legally as 'research only'” | E | No | High | MHRA treats Melanotan II as a POM; 'research only' labelling does not make sale to consumers for human use lawful. |
09Safety uncertainty score
Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.
10Known adverse signals
- Mole changes and case reports of subsequent melanoma diagnoses
- Severe nausea and vomiting
- Cardiovascular events including hypertension and arrhythmia
- Hospital admissions documented in UK case series
- MHRA has issued repeated public-health warnings
11Drug-interaction uncertainty
Drug-interaction picture not characterised for this peptide. Treat absence as uncertainty.
12Anti-doping status
13UK legal position
Not licensed for any indication. Classified as a prescription-only medicine (POM) due to pharmacological activity. MHRA has issued warnings against use.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Not approved for any indication. Regulatory warnings issued in multiple member states.
15What this page cannot tell you
- Whether any dose of Melanotan II is safe for you — there is no lawful UK clinical guidance.
- What is actually in a vial purchased outside the regulated chain.
- Whether existing moles are at increased risk from MT-II exposure.
- What the long-term cancer-related effects of repeated systemic alpha-MSH stimulation are.
16Last reviewed
17Citation quality score
18Research gaps
- No completed UK RCTs at any dose for cosmetic tanning.
- Long-term melanoma-incidence studies in users are lacking.
- Pharmacokinetics in grey-market product is not characterised.
19Safer alternatives / established care pathways
- Self-tanning lotions, mousses, and gradual tanning moisturisers.
- Professional spray-tan services.
- Sun-protective behaviour. The MHRA, NHS, and dermatology bodies advise against melanotan because the safety record is poor and no licensed alternative exists.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What does the MHRA say about Melanotan II for cosmetic tanning?
- What documented side effects should I look out for?
- Are existing moles a particular concern for me?
- If I'm interested in PT-141 for sexual dysfunction, is there a licensed alternative?
- How should I report a side effect or suspected adverse event?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Increased skin pigmentation without UV exposure
- 2Potential protective melanin against UV damage
- 3Enhanced erectile function in males
- 4Increased sexual arousal in both sexes
- 5Possible appetite-suppressing effects
- 6Accelerated tanning response to minimal UV exposure
Claim vs Evidence
How popular claims about Melanotan II stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Safe sunless tanning” | E | No | High | Documented adverse effects include nausea, blood-pressure changes, and effects on moles. No UK regulator has assessed it as safe for cosmetic tanning. |
| “Prevents skin cancer by replacing UV exposure” | E | No | High | There is no evidence Melanotan II reduces skin-cancer risk in humans, and effects on existing moles are a concern. |
| “Improves libido and erectile function” | C | Limited | High | Some preclinical and limited human signals exist; the derivative PT-141 (bremelanotide) is the licensed melanocortin product for sexual dysfunction in some jurisdictions, not Melanotan II. |
| “Sold legally as 'research only'” | E | No | High | MHRA treats Melanotan II as a POM; 'research only' labelling does not make sale to consumers for human use lawful. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 0.25-0.5 mg initially, titrating up to 0.5-1 mg (from research literature) |
| Frequency | Daily during loading phase, then maintenance 1-2 times weekly |
| Duration | Loading phase typically 2-4 weeks; maintenance ongoing |
| Notes | ⚠️ Melanotan II is not approved for human use. These protocols are extrapolated from research literature and anecdotal reports only. Significant safety concerns exist. Medical supervision is essential if considering any melanotropic peptide. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (most common research route)
- Nasal spray (less bioavailable; historically marketed illegally)
| Half-Life | Stability |
|---|---|
| Approximately 1 hour in circulation | Lyophilised powder stable when stored at -20°C; reconstituted solution should be refrigerated and used promptly |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea and vomiting (especially early doses)
- Facial flushing
- Fatigue and lethargy
- Spontaneous erections
- Increased libido
- Injection site reactions
- Headache
Rare Risks & Concerns
- Changes to existing moles (darkening, growth)
- New mole development (new nevi)
- Theoretical melanoma concern with stimulation of melanocytes
- Cardiovascular effects (elevated blood pressure)
- Priapism (prolonged erection)
- Long-term effects on pigmentation unknown
- Potential psychological effects on body image
Contraindications
- Personal or family history of melanoma
- Multiple atypical moles or dysplastic naevus syndrome
- Pregnancy and breastfeeding
- Cardiovascular disease
- Current skin cancers or suspicious lesions
- Children and adolescents
- Autoimmune skin conditions
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for any indication. Classified as a prescription-only medicine (POM) due to pharmacological activity. MHRA has issued warnings against use.
🇪🇺 European Union
Not approved for any indication. Regulatory warnings issued in multiple member states.
Clinical Studies Summary
Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.
The erectogenic properties of Melanotan II are not limited to cases of psychogenic erectile dysfunction; men with a variety of organic risk factors developed penile erections. The finding of increased sexual desire warrants further investigation of centrally acting agents on disorders of sexual desire.
Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.
Our findings warrant further investigation of melanocortin agonists and antagonists on penile erection. International Journal of Impotence Research (2000) 12, Suppl 4, S74-S79.
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.
Melanotan-II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
The recommended single MT-II dose for future Phase I studies is 0. 025 mg/kg/day.
Melanotan II: a possible cause of renal infarction: review of the literature and case report.
We present a review of Melanotan II and the possible effects of this drug on the kidneys by including a case of a renal infarction most likely attributed to Melanotan II. In the mechanism of renal injury with Melanotan II, thrombotic pharmacological influence and possible direct toxic effect on renal parenchyma must be considered.
Falsification of biotechnology drugs: current dangers and/or future disasters?
Next, we describe the identification strategy utilised by our lab to identify the API in falsified biotherapeutics, followed by a discussion of the putative hazards due to impurities and contaminations that were found or could be encountered in falsified biotherapeutics. Finally, we terminate with an educational prediction of what may happen in the future and possible ways to counteract putative future disasters.
Registered Trials & Regulatory Status
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
Status: Recruiting · 60 participants · Hudson Biotech
Conditions: NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)
Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)
Status: Withdrawn · Resilient Pharmaceuticals
Conditions: Psychological Effects of Study Drug
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Melanotan II?
Source research-grade Melanotan II from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Melanotan II
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What does the MHRA say about Melanotan II for cosmetic tanning?
- What documented side effects should I look out for?
- Are existing moles a particular concern for me?
- If I'm interested in PT-141 for sexual dysfunction, is there a licensed alternative?
- How should I report a side effect or suspected adverse event?
UK regulatory & safety context
Related Research Guides
Related Peptides
PT-141
An FDA-approved melanocortin receptor agonist for treatment of hypoactive sexual desire disorder in premenopausal women.
Learn moreAlpha-MSH
A melanocortin peptide with pigmentation, anti-inflammatory, and appetite-regulating effects, the natural basis for several therapeutic developments.
Learn more